Amir R. Vosoughi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amir R. Vosoughi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Andrew Micieli
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
3 shared publications - Brendan K. Tao
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada
2 shared publications Guhan Sivakumar
Faculty of Health, University of Waterloo, Waterloo, ON, Canada
2 shared publications- Rachel Leong
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
2 shared publications - Ahsen Hussain
Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Canada
1 shared publication - Bryan Arthurs
McGill University
1 shared publication
Latest Publications
- 28 August 2025
- Published by Taylor & Francis in Orbit
- Vol. 44 (6) , 898-905
Prevalence of phantom eye syndrome following eye removal: a systematic review and meta-analysis
To determine the literature-pooled prevalence of phantom eye syndrome (PES) following eye removal, including phantom vision (PV), phantom pain (PP), or phantom non-visual non-painful (PNVNP) sensations. Databases were searched from inception to March 12 2025. A systematic review and meta-analysis of PES prevalence and risk factors was conducted. Seven studies were identified (775 patients). The literature-pooled prevalence of PES, defined as having at least one constitutive symptom, was 58.9% (95% CI [50.4, 66.9], I2 = 78%, five studies). The most common constitutive symptom was PV in 35.6% (95% CI [29.5, 42.3], I2 = 71.1%, six studies), followed by PP in 26.4% (95% CI [20.8, 32.9], I2 = 76.1%, seven studies) and PNVNP in 19.9% (95% CI [7.9, 42.0], I2 = 91.2%, six studies) sensations. The pooled prevalence of reporting all three constitutive symptoms simultaneously was 4.8% (95% CI [2.2, 10.1], I2 = 67.3%, three studies). Commonly reported risk factors in the literature included mental health comorbidities and preoperative pain, though some studies did not conduct multivariable analysis to control for confounding factors. Low certainty evidence supports that over 50% of patients may develop at least one constitutive PES symptom. Patients may benefit from PES screening, reassurance, and early treatment of postoperative pain.
- 28 August 2025
- Published by Taylor & Francis in Orbit
- Vol. 44 (6) , 898-905
Prevalence of phantom eye syndrome following eye removal: a systematic review and meta-analysis
To determine the literature-pooled prevalence of phantom eye syndrome (PES) following eye removal, including phantom vision (PV), phantom pain (PP), or phantom non-visual non-painful (PNVNP) sensations. Databases were searched from inception to March 12 2025. A systematic review and meta-analysis of PES prevalence and risk factors was conducted. Seven studies were identified (775 patients). The literature-pooled prevalence of PES, defined as having at least one constitutive symptom, was 58.9% (95% CI [50.4, 66.9], I2 = 78%, five studies). The most common constitutive symptom was PV in 35.6% (95% CI [29.5, 42.3], I2 = 71.1%, six studies), followed by PP in 26.4% (95% CI [20.8, 32.9], I2 = 76.1%, seven studies) and PNVNP in 19.9% (95% CI [7.9, 42.0], I2 = 91.2%, six studies) sensations. The pooled prevalence of reporting all three constitutive symptoms simultaneously was 4.8% (95% CI [2.2, 10.1], I2 = 67.3%, three studies). Commonly reported risk factors in the literature included mental health comorbidities and preoperative pain, though some studies did not conduct multivariable analysis to control for confounding factors. Low certainty evidence supports that over 50% of patients may develop at least one constitutive PES symptom. Patients may benefit from PES screening, reassurance, and early treatment of postoperative pain.
- Open Access
- 14 April 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (5) , e700-e706
The use of non-person-first language in neuro-ophthalmology referrals
- 14 April 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (5) , e700-e706
Open AccessThe use of non-person-first language in neuro-ophthalmology referrals
- Open Access
- 18 June 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 267, 1-7
The Use of Non-Person-First Language in Consecutive General Ophthalmology Referrals
- 18 June 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 267, 1-7
Open AccessThe Use of Non-Person-First Language in Consecutive General Ophthalmology Referrals
- 1 May 2024
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 50 (5) , 460-467
Diversity in enrollment to clinical trials for cataract medicine and surgery: meta-analysis
Purpose: To investigate sex, racial, and ethnic disparities in patient enrollment across cataract trials registered in the United States. Setting: Participants enrolled in high-quality (reduced risk of bias), U.S.-registered (on ClinicalTrials.gov), cataract-related randomized controlled trials (RCTs). RCTs must be completed, have used double or greater masking, and have published results through the registry or a scholarly journal. Design: Cross-sectional database study. Methods: Trial (study sponsor country, study site location, trial initiation year, study phase, and study masking) and demographic data (sex, race, and ethnicity according to U.S. reporting guidelines) were collected. The Global Burden of Disease database provided sex-based cataract disease burdens. Pooled participation-to-prevalence ratios (PPRs) with 95% CIs were calculated for female sex, with values between 0.8 and 1.2 constituting sufficient study enrollment. Kruskal-Wallis tests (α = 0.05) with subsequent post hoc comparisons were used to evaluate demographic representations stratified by trial characteristics. Results: From 864 records, 100 clinical trials (N = 67 874) were identified, of which 97 (N = 67 697) reported sex demographics with a pooled female PPR of 0.89 (95% CI, 0.85-0.94). Of the 67 697 total participants, the absolute female enrollment was 19 062 (28.16%). Ethnicity and race were reported in 9 (N = 1792) and 26 trials (N = 23 181), respectively. Among trials that reported race, most were White (N = 19 574; 84.44%). Conclusions: High-quality, U.S.-registered, cataract trials enrolled acceptable proportions of women. However, the absolute number of female and racialized participants was low. Race and ethnicity were underreported. Disparity trends predominately held across secondary variables. To promote generalizability, future trials should pursue equitable demographic enrollment.
- 1 May 2024
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 50 (5) , 460-467
Diversity in enrollment to clinical trials for cataract medicine and surgery: meta-analysis
Purpose: To investigate sex, racial, and ethnic disparities in patient enrollment across cataract trials registered in the United States. Setting: Participants enrolled in high-quality (reduced risk of bias), U.S.-registered (on ClinicalTrials.gov), cataract-related randomized controlled trials (RCTs). RCTs must be completed, have used double or greater masking, and have published results through the registry or a scholarly journal. Design: Cross-sectional database study. Methods: Trial (study sponsor country, study site location, trial initiation year, study phase, and study masking) and demographic data (sex, race, and ethnicity according to U.S. reporting guidelines) were collected. The Global Burden of Disease database provided sex-based cataract disease burdens. Pooled participation-to-prevalence ratios (PPRs) with 95% CIs were calculated for female sex, with values between 0.8 and 1.2 constituting sufficient study enrollment. Kruskal-Wallis tests (α = 0.05) with subsequent post hoc comparisons were used to evaluate demographic representations stratified by trial characteristics. Results: From 864 records, 100 clinical trials (N = 67 874) were identified, of which 97 (N = 67 697) reported sex demographics with a pooled female PPR of 0.89 (95% CI, 0.85-0.94). Of the 67 697 total participants, the absolute female enrollment was 19 062 (28.16%). Ethnicity and race were reported in 9 (N = 1792) and 26 trials (N = 23 181), respectively. Among trials that reported race, most were White (N = 19 574; 84.44%). Conclusions: High-quality, U.S.-registered, cataract trials enrolled acceptable proportions of women. However, the absolute number of female and racialized participants was low. Race and ethnicity were underreported. Disparity trends predominately held across secondary variables. To promote generalizability, future trials should pursue equitable demographic enrollment.
- 17 August 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (5) , 324-328
Anemia and idiopathic intracranial hypertension: a prospective study
- 17 August 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (5) , 324-328
Anemia and idiopathic intracranial hypertension: a prospective study